Search Within

Andrew Jeffrey Dunbar

Formats
  1. Journal Article (19)
  2. Meeting Abstract (18)
  3. Guidelines (3)
  4. Research Letter (2)
  5. Editorial (1)
  6. Review (1)
Groups
  1. Department of Medicine (44)
  2. Hematologic Malignancies, Division of (44)
  3. Center for Hematologic Malignancies (40)
  4. Adult Leukemia (37)
  5. Executive Committee, Center for Hematologic Malignancies (35)
  6. GSK Faculty (35)

More Groups

People
  1. Ross Levine (35)
  2. Sheng Cai (14)
  3. Sean Devlin (12)
  4. Young Park (12)
  5. Jacob Glass (10)
  6. Aaron Goldberg (9)

More People

Years
  1. 2024 (9)
  2. 2023 (3)
  3. 2022 (5)
  4. 2021 (6)
  5. 2020 (10)
  6. 2019 (8)

More Years

Publications
  1. Blood (19)
  2. Haematologica (4)
  3. Journal of the National Comprehensive Cancer Network (3)
  4. American Journal of Hematology (2)
  5. Blood Advances (2)
  6. Cell Reports (2)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. Ferrata Storti Foundation (4)
  3. Cell Press (3)
  4. Harborside Press (3)
  5. American Association for Cancer Research (2)
  6. John Wiley & Sons, Inc. (2)

More Publishers

Results (44)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis
    Journal Article

    Dunbar, A. J.; Kim, D.; Lu, M.; Farina, M.; Bowman, R. L.; Yang, J. L.; Park, Y.; Karzai, A.; Xiao, W.; Zaroogian, Z.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
    Journal Article

    Stahl, M.; Derkach, A.; Farnoud, N.; Bewersdorf, J. P.; Robinson, T.; Famulare, C.; Cho, C.; Devlin, S.; Menghrajani, K.; Patel, M. A.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • The second generation type II JAK2 inhibitor, AJ1-10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I JAK2 inhibitors in models of myeloproliferative neoplasms (MPNs)
    Meeting Abstract

    Rai, S.; Stetka, J.; Usart, M.; Hao-Shen, H.; Park, Y.; Houston, R.; Martinez Benitez, A. R.; Wereski, M.; Guzzardi, E.; Persaud, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A risk-adapted study to assess the efficacy of enasidenib and subsequent response-driven addition of azacitidine for newly diagnosed IDH2-mutant AML patients: 3-year follow-up
    Meeting Abstract

    Stein, E.; Cai, S. F.; Huang, Y.; Dunbar, A.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Schiller, G. J.; Olin, R. L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • JAK2(V617F) reversible activation shows an essential requirement for JAK2(V617F) in myeloproliferative neoplasms (MPNs)
    Meeting Abstract

    Dunbar, A.; Bowman, R. L.; Park, Y.; Izzo, F.; Myers, R. M.; Karzai, A.; Kim, W. J.; Maestre, I. F.; Waarts, M. R.; Nazir, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Myeloproliferative Neoplasms, version 3.2022, NCCN Clinical Practice Guidelines in Oncology
    Guidelines

    Gerds, A. T.; Gotlib, J.; Ali, H.; Bose, P.; Dunbar, A.; Elshoury, A.; George, T. I.; Gundabolu, K.; Hexner, E.; Hobbs, G. S.; more...
    Journal of the National Comprehensive Cancer Network (2022)

    Fulltext@MSK | Save
  • The CXCR1/CXCR2 inhibitor reparixin alters the development of myelofibrosis in the Gata1(low) mice
    Journal Article

    Verachi, P.; Gobbo, F.; Martelli, F.; Martinelli, A.; Sarli, G.; Dunbar, A.; Levine, R. L.; Hoffman, R.; Massucci, M. T.; Brandolini, L.; more...
    Frontiers in Oncology (2022)

    Fulltext@MSK | Save
  • Germline RUNX1 mutations induce inflammation in hematopoietic stem and progenitor cells and predispose to hematologic malignancies
    Meeting Abstract

    Ahmad, M. H.; Hegde, M.; Wong, W. J.; Dunbar, A.; Carrascoso, A.; Garett, L. J.; Ferreira, N. K.; Liu, H.; Li, R.; Eberg, B. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Comparative mutational profiling of hematopoietic progenitor cells and circulating endothelial cells (CECs) in patients with primary myelofibrosis
    Journal Article

    Farina, M.; Bernardi, S.; Polverelli, N.; D’Adda, M.; Malagola, M.; Bosio, K.; Re, F.; Almici, C.; Dunbar, A.; Levine, R. L.; more...
    Cells (2021)

    Fulltext@MSK | Save
  • Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors
    Journal Article

    Dunbar, A.; Bolton, K. L.; Devlin, S. M.; Sanchez-Vega, F.; Gao, J.; Mones, J. V.; Wills, J.; Kelly, D.; Farina, M.; Cordner, K. B.; more...
    Blood (2021)

    Fulltext@MSK | Save